ReviewInternational journal of women's health2013
Female pattern alopecia: current perspectives.
Review in International journal of women's health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions for female pattern hair loss.The Cochrane database of systematic reviews · 2016Pooled it
- Efficacy and Safety of Microneedling Combined With Mesotherapy for Androgenic Alopecia: A Retrospective Study Comparing Four Treatment Protocols.Health science reports · 2026Article
- Advances in Medicalized Hair Loss Solutions: A Review of Current Clinical Practices and Regenerative Medicine-Based Protocols with Focus on Off-Label Injectable Treatments.Journal of clinical medicine · 2026Review
- Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeutic treatment to androgenic alopecia.Annals of medicine and surgery (2012) · 2025Review
- Androgenetic alopecia.Nature reviews. Disease primers · 2025Review
- Global sex disparities in lifetime risk of alopecia areata: a systematic analysis from the global burden of disease study, 1990 to 2021.Biology of sex differences · 2025Article
- Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia.Pharmaceutics · 2025Review
- Advances in Research on Concentrated Growth Factor Applications for Androgenetic Alopecia Treatment: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
- From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Androgenetic alopecia: An update.JAAD international · 2023Review
- Article
- Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?Current oncology (Toronto, Ont.) · 2023Review
- Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss.Journal of clinical medicine · 2023Review
- The role ofPostepy dermatologii i alergologii · 2022Article
- Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy.Yonsei medical journal · 2022Article
- Biological Efficacy Evaluation of a Non-Cross-Linked Hyaluronic Acid Dermal Filler for Biomedical Application in Inflammatory Scalp Conditions.Life (Basel, Switzerland) · 2021Article
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.Journal of cosmetic dermatology · 2021Review
- An anti-hair loss treatment in the management of mild androgenetic alopecia: Results from a large, international observational study.Dermatologic therapy · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hair loss is a commonly encountered problem in clinical practice, with men presenting with a distinctive pattern involving hairline recession and vertex balding (Norwood-Hamilton classification) and women exhibiting diffuse hair thinning over the crown (increased part width) and sparing of the frontal hairline (Ludwig classification). Female pattern hair loss has a strikingly overwhelming psychological effect; thus, successful treatments are necessary. Difficulty lies in successful treatment interventions, as only two medications - minoxidil and finasteride - are approved for the treatment of androgenetic alopecia, and these medications offer mediocre results, lack of a permanent cure, and potential complications. Hair transplantation is the only current successful permanent option, and it requires surgical procedures. Several other medical options, such as antiandrogens (eg, spironolactone, oral contraceptives, cyproterone, flutamide, dutasteride), prostaglandin analogs (eg, bimatoprost, latanoprost), and ketoconazole are reported to be beneficial. Laser and light therapies have also become popular despite the lack of a profound benefit. Management of expectations is crucial, and the aim of therapy, given the current therapeutic options, is to slow or stop disease progression with contentment despite patient expectations of permanent hair regrowth. This article reviews current perspectives on therapeutic options for female pattern hair loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.